Adaptive Therapy for Resected Stage ⅠA2-Ⅱ NSCLC Patients With Undetectable MRD
Recruiting now · Not applicable
Conditions studied: NSCLC
In brief
It is a prospective, multicenter, randomized controlled trial to investigate the predictive value of MRD on adjuvant therapy. Stage IA2-II resected NSCLC patients will undergo two-round MRD tests after surgery, first in 3-7 days and second in 1 month after surgery. And patients who confirm two-round landmark undetectable MRD will be enrolled and randomly assigned to the conventional treatment group or the adaptive therapy group . Patients in the the adaptive therapy group will undergo closely MRD and imaging monitoring without adjuvant therapy if the MRD was negative.
Key facts
- Study ID
- NCT06924710
- Run by
- Peking University Cancer Hospital & Institute
- People needed
- 286
- Starts
- 2025-04-06
- Expected to finish
- 2029-12-31
- Last updated by the study team
- 2025-10-02
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Stage IA2-II non-small cell cancer patients who after complete resection.
- Two-round MRD tests confirm landmark undetectable MRD
- Expected survival ≥24 months
- ECOG PS 0-1
- Willing to accept MRD monitoring every 3 months for a total of 2 years after surgery
You may not qualify if…
- Patients who had previously undergone radiotherapy or chemotherapy or any other anti-tumor therapy
- Patients with a history of other malignancies in the past 5 years
- Any unstable systemic disease (eg, active infection, high-risk hypertension, unstable angina, congestive heart failure, etc.) or other conditions that investigators considered would limit the ability of the patient to participate in the study
Where it is running
- Peking University Cancer Hospital & Institute — Beijing, Beijing Municipality, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.